AU2003264195A8 - Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system - Google Patents

Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system

Info

Publication number
AU2003264195A8
AU2003264195A8 AU2003264195A AU2003264195A AU2003264195A8 AU 2003264195 A8 AU2003264195 A8 AU 2003264195A8 AU 2003264195 A AU2003264195 A AU 2003264195A AU 2003264195 A AU2003264195 A AU 2003264195A AU 2003264195 A8 AU2003264195 A8 AU 2003264195A8
Authority
AU
Australia
Prior art keywords
guanosine
inosine
injuries
treatment
nervous system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU2003264195A
Other versions
AU2003264195A1 (en
Inventor
Michel P Rathbone
Sonya Kleywegt
Francesco Caciagli
Eva Vertes
Patrizia Di Iorio
Eva Susanne Werstiuk
Renata Ciccarelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUROLOGICAL TECHNOLOGIES Inc
Original Assignee
NEUROLOGICAL TECHNOLOGIES Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEUROLOGICAL TECHNOLOGIES Inc filed Critical NEUROLOGICAL TECHNOLOGIES Inc
Publication of AU2003264195A1 publication Critical patent/AU2003264195A1/en
Publication of AU2003264195A8 publication Critical patent/AU2003264195A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003264195A 2002-09-03 2003-09-03 Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system Abandoned AU2003264195A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40731002P 2002-09-03 2002-09-03
US60/407,310 2002-09-03
PCT/CA2003/001291 WO2004022039A2 (en) 2002-09-03 2003-09-03 Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system

Publications (2)

Publication Number Publication Date
AU2003264195A1 AU2003264195A1 (en) 2004-03-29
AU2003264195A8 true AU2003264195A8 (en) 2008-02-28

Family

ID=31978454

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003264195A Abandoned AU2003264195A1 (en) 2002-09-03 2003-09-03 Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system

Country Status (3)

Country Link
AU (1) AU2003264195A1 (en)
CA (1) CA2497437A1 (en)
WO (1) WO2004022039A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016359A1 (en) * 2003-08-19 2005-02-24 Neurological Technologies Inc. Method of promoting remyelination
RU2311180C2 (en) * 2005-04-28 2007-11-27 Галина Викторовна Сукоян Agent for preventing progression of apoptotic and arresting necrotic alterations in body tissue
AR058834A1 (en) * 2006-11-06 2008-02-27 Univ Nac Quilmes A COMPOSITE WITH INHIBITORY ACTIVITY OF A RHO-GTPASA CELL PROTEIN, A PROCEDURE FOR OBTAINING IT, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE IT AND A METHOD FOR THE TREATMENT OF AN INDICATION MEDIATED BY A RHO-GTPASA CELL PROTEIN

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692784B1 (en) * 1992-06-24 1995-06-30 Pf Medicament USE OF GUANOSINE, ITS PRECURSORS AND DERIVATIVES FOR THE MANUFACTURE OF MEDICINES FOR TREATING CEREBRAL FUNCTIONAL DEFICITS.
US6440455B1 (en) * 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons

Also Published As

Publication number Publication date
AU2003264195A1 (en) 2004-03-29
CA2497437A1 (en) 2004-03-18
WO2004022039A2 (en) 2004-03-18
WO2004022039A3 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
HRP20130602T1 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
HK1226399A1 (en) Pyridazine derivatives and their use as therapeutic agents
IL172418A0 (en) Therapeutic agents useful for treating pain
PT2942082T (en) A2a receptor antogonists for use in the treatment of movement disorders
GB0520687D0 (en) Skin treatment formulations
SI1603915T1 (en) SUBSTITUTED 8 -PYRIDINYL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE AND 8 -PYRIMIDIN YL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE DERIVATIVES AND THEIR USE AGAINST NEUROGENERATIVE DISEASES
HUS1300035I1 (en) Use of dihydroimidazolones for the treatment of epilepsy in dogs
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
PL368556A1 (en) Methods for treating or preventing skin disorders using cd2-binding agents
IL157592A0 (en) Carbamate compounds for use in preventing or treating movement disorders
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
AU2003264195A8 (en) Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system
TWI365187B (en) 7-azaindoles and the use thereof as therapeutic agents
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
AU2002314594A8 (en) Cinnamic acid dimers, their preparation and the use thereof for treating neurodegenerative disease
GB0310147D0 (en) A composition for use in the treatment of a skin condition in a subject
SI1656372T1 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
ZA200200374B (en) Apparatus for the treatment of muscular and skeletal injuries.
GB0305416D0 (en) Sheet or the like, for topical therapeutic use, and process for its preparation
HK1113139A1 (en) Therapeutic agents useful for treating pain
GB0319375D0 (en) Skin treatment
ZA200307477B (en) Carbamate compounds for use in preventing or treating movement disorders.
GB0203173D0 (en) The treatment of neurodegenerative disease
GB0224146D0 (en) Skin treatment materials
GB0212208D0 (en) Skin treatment materials

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase